ABBV vs LLY
AbbVie and Lilly (Eli), both Healthcare
Lilly (Eli) is the larger company at $980B against $382B. On trailing earnings LLY is the cheaper of the two at a P/E of 37.7 against 70.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +61% against +23% for ABBV. Ryufin's sector-relative Smart Score puts LLY ahead, 8/10 against 5/10.
| Figure | ABBV | LLY |
|---|---|---|
| Last close | $249 | $1124 |
| Market cap | $382B | $980B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 70.3 | 37.7 |
| Dividend yield | 2.7% | 0.6% |
| 1-year return | +23% | +61% |
| 5-year return | +159% | +337% |
| Ryufin Smart Scoresector-relative, 1–10 | 5/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Lilly (Eli)
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.